ClinicalTrials.gg
CompletedNCT03484793AESOPUpdated Apr 3, 2018

Reduce Medication Errors by Translating AESOP Model Into CPOE Systems

An interventional study of AESOP service system in Hypertension, sponsored by Taipei Medical University. Completed at 1 site in Taiwan. Per ClinicalTrials.gov, last updated 2018-04-03.

Sponsored by Taipei Medical University · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled May 2017, registered Mar 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
37
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 117 studies in Hypertension with a site in Taiwan — 18 open to participants now, 21 under way, 5 of them phase 3. Hypertension · Taiwan.

Enrollment
84th of 90
37 · median 233
Started
2017
with 3 others
No phase
30 of 117
7 open now
Registered
68th of 117
by date

Among the 117 studies in Hypertension with a site in Taiwan, this one is the 84th largest by enrollment of the 90 interventional ones that give a count, is one of 4 that started in 2017, is one of 30 with no phase, and was the 68th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

18 of the 117 studies in Hypertension with a site in Taiwan are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 117 studies in Hypertension with a site in Taiwan, or all of them as a file.
02

Study summary

Medication errors are common, life-threatening, costly but preventable. Information technology and automated systems are highly efficient for preventing medication errors and therefore widely employed in hospital settings. In this study, investigators would perform a cluster randomized controlled trial of a clinical reminding system that uses DNN and Probabilistic models to detect and notify physicians of inappropriate prescriptions, giving them the opportunity to correct these gaps and increase prescriptions completeness. This study aim is to assess whether or not this system would improve prescription notation for a broad array of patient conditions.

Read the detailed description

This paper focuses on "Big data" in the knowledge base, using "Data minig" study of DM (Disease-Medication) and MM (Medication-Medication) of relevance to develop associated decision resources system-"the intelligent safety system" (Advanced Electronic Safety of Prescriptions,AESOP Model), and test the system in the clinical environment in hospital can assist physicians when open orders reduce medication errors, the system is named "AESOP Model".

03

Conditions studied

  • Hypertension

Keywords

  • AESOP Model
  • Big data
  • medication error
  • data mining
  • patient safety
  • CPOE
  • CDSS
  • alarm fatigue
  • association rule mining.
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Physicians who are working at the outpatient clinics in hospitals.
  • Physicians who sign the consent form

Exclusion criteria

Exclusion Criteria:

  • Physicians who are unable to participate in this trial for the whole process
  • Physicians who do not sign the consent form
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    AESOP integrated to CPOE for reducing medication errors

    18 were assigned to the experimental group

    Other: AESOP service system

  • No intervention
    Non AESOP

    19 were assigned to the traditional CPOE system

Interventions

  • OtherAESOP service system

    Investigators develop an electronic reminder in CPOE system which notifies physicians when there appears to be an inappropriate prescription. At the time, a physician saves a typed prescription, our system analyzes the patient's medications, diseases and uses the knowledge base to determine whether a medication is uncommonly prescribed to all diseases in a given prescription. If the system detects the common associations of medications and diseases in a given prescription, it considers an appropriate prescription, and, if not, an actionable reminder is shown onscreen. To the right of each suggested uncommon medication is a reason why the reminder is appearing. Physicians can accept the reminder or ignore the reminder.

06

What researchers measure

Primary outcomes

  1. The acceptance rate of reminder between two groups intervention and control

    The primary outcome of this study is the acceptance rate of the reminder, defined as the number of reminders accepted divided by number of unique reminders presented. In certain instances, physicians might see the same reminder serially, so we aggregate presentations and acceptance of the same reminder for the same patients' prescriptions in our calculation of the acceptance rate.

    Time frame: 3 months

Secondary outcomes

  1. The changes in the number of reminder for each group

    As a secondary outcome, we measure the number of inappropriate prescriptions rate documented in the two groups during the two time periods and calculate the unadjusted relative rate of inappropriateness notation in the intervention group by comparing the number of inappropriateness recorded in the intervention arm during the intervention period to all other groups. The unadjusted relative rate is defined as the ratio (errorsintervention-post/errorscontrol-post)/ (errorsintervention-pre/errorscontrol-pre).

    Time frame: 3 months

07

Study locations

1 site
  • TMU-Shuang-Ho Hospital
    Taipei, Taiwan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Dec 2017, 7 months.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 7 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2018
First posted
Apr 2, 2018
StartActual
May 1, 2017
Primary completionActual
Dec 31, 2017
CompletionActual
Feb 28, 2018
Last update
Apr 3, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03484793
Collaborators
Ministry of Science and Technology, Taiwan, Taipei Medical University Shuang Ho Hospital, Taiwan College of Healthcare Executives, Taipei Medical University Taipei Municipal Wan Fang Hospital, Case Western Reserve University, Cardinal Tien Hospital, Yong He Cardinal Tien Hospital, Chang Hua Christian Hospital, Taipei Medical University Hospital
Responsible party
Sponsor
First posted
Apr 2, 2018
Start date
May 1, 2017
Primary completion
Dec 31, 2017
Completion
Feb 28, 2018
Last update
Apr 3, 2018

Study contacts

Yu-Chuan MD Li, PhD
study chair · Taipei Medical University
Chuya Huang, MA
study director · Taipei Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion